Last reviewed · How we verify
Placebo transdermal three 90 μL sprays
Placebo transdermal three 90 μL sprays is a Small molecule drug developed by Lumara Health, Inc.. It is currently in Phase 3 development for Control arm in phase 3 clinical trial (specific indication unknown).
This is a placebo formulation with no active pharmacological mechanism.
This is a placebo formulation with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trial (specific indication unknown).
At a glance
| Generic name | Placebo transdermal three 90 μL sprays |
|---|---|
| Sponsor | Lumara Health, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo products contain no active pharmaceutical ingredient and produce therapeutic effects solely through the placebo effect—patient expectation and psychological mechanisms. This particular placebo is administered as a transdermal spray in three 90 μL doses. It is used as a control arm in clinical trials to establish efficacy of active comparator drugs.
Approved indications
- Control arm in phase 3 clinical trial (specific indication unknown)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo transdermal three 90 μL sprays CI brief — competitive landscape report
- Placebo transdermal three 90 μL sprays updates RSS · CI watch RSS
- Lumara Health, Inc. portfolio CI